## Supplementary table 1

| Mitogens | 6h Untreated | 24h Untreated | 72h Untreated |
| :---: | :---: | :---: | :---: |
| CRP mouse | 78.5\% $\pm 27.3$ | $14.2 \% \pm 8.3$ | $31.7 \% \pm 4.1$ |
| M-CSF | 18.5\% $\pm 18.1$ | $-32.2 \% \pm 16.1$ | $-41.5 \% \pm 0.5^{*}$ |
| EGF | $17.1 \% \pm 6.7$ | $26.5 \% \pm 19.5$ | 20.2\% $\pm 11.8$ |
| IL-3 | $-5.3 \% \pm 16$. | $14.0 \% \pm 39.0$ | $31.1 \% \pm 29.1$ |
| FGF basic | $-0.3 \% \pm 24.9$ | 0.4\% $\pm 5.2$ | $-25.5 \% \pm 10.1$ |
| SCF | $-20.6 \% \pm 23.6$ | $-64.3 \% \pm 1.2$ | $-57.3 \% \pm 1.7$ |
| GM-CSF | $-30.7 \% \pm 14.2$ | $-35.4 \% \pm 2.1$ | $27.9 \% \pm 36.7$ |
| FGF-9 | $-21.4 \% \pm 16.8$ | - | $-31.5 \% \pm 13.5$ |
| TPO | - | - | - |
| IL-5 | - | - | - |
| Pro-inflammatory | 6 h Untreated | 24h Untreated | 72h Untreated |
| IFN Y | $-13.9 \% \pm 20.3$ | $-40.7 \% \pm 5.4$ | $-22.8 \% \pm 5.9$ |
| IL-17a | - | 56.5.5\% $\pm 0$ | $-14.6 \% \pm 13.4$ |
| Oncostatin M | $-11.9 \% \pm 17.1$ | $-39.9 \% \pm 12.2$ | $-51.8 \% \pm 0.9$ |
| IL-6 | $-57.4 \% \pm 4.7$ | $-72.9 \% \pm 0.5$ | $-68.6 \% \pm 1.8$ |
| IL-12p70 | - | $-49.4 \% \pm 7.9$ | - |
| $\mathrm{IL}-1 \alpha$ | $-29.6 \% \pm 11.8$ | $-48.6 \% \pm 1.9$ | $-45.3 \% \pm 2.6$ |
| IL-18 | $152.9 \% \pm 204.7$ | $64.6 \% \pm 69.0$ | - |
| TNF $\alpha$ | $19.6 \% \pm 16.8$ | $-51.5 \% \pm 5.0$ | $-47.6 \% \pm 6.3$ |
| CD40 ligand | - | - | - |
| IL-1 $\beta$ | $31.9 \% \pm 33.9$ | $-74.9 \% \pm 25.1$ | $0.7 \% \pm 57.7$ |
| Vascular/haematological | 6 h Untreated | 24h Untreated | 72h Untreated |
| Tissue Factor | $168.5 \% \pm 76.4$ | $237.6 \% \pm 56.7$ | 97.3\% $\pm 84.5$ * |
| Haptoglobin | $3.2 \% \pm 6.0$ | $-15.3 \% \pm 4.9$ | $10.1 \% \pm 14.8$ |
| VEGF | $3.9 \% \pm 26.7$ | $1.2 \% \pm 23.0$ | $-0.3 \% \pm 2.5$ |
| Endothelin | $17.9 \% \pm 25.0$ | $4.8 \% \pm 25.6$ | $10.6 \% \pm 72.2$ |
| Factor VII | $4.9 \% \pm 5.5$ | $-8.2 \% \pm 14.2$ | $-8.9 \% \pm 5.6$ |
| Fibrinogen | $10.8 \% \pm 7.4$ | $7.6 \% \pm 8.0$ | $6.2 \% \pm 1.0$ |
| MPO | - | - | - |
| SAP | - | - | - |
| vWF | - | - | - |
| Chemokines | 6h Untreated | 24h Untreated | 72h Untreated |
| Eotaxin | $39.2 \% \pm 47.1$ | $-44.7 \% \pm 0$ | $-55.9 \% \pm 15.2$ |
| MIP-1 $\alpha$ | $10.1 \% \pm 2.8$ | $-6.8 \% \pm 11.8$ | $-44.1 \% \pm 3.6$ |
| MCP-3 | $-68.1 \% \pm 5.3$ | $-74.8 \% \pm 6.7$ | $-82.1 \% \pm 0.5$ |
| MCP-1 | $-63.2 \% \pm 5.8$ | $-74.1 \% \pm 7.4$ | $-81.5 \% \pm 0.5$ |
| KC/GRO $\alpha$ | - | - | $-93.7 \% \pm 0.2$ |
| Lymphotactin | $8.9 \% \pm 13.1$ | $-40.2 \% \pm 21.0$ | -41.9\% $\pm 0.9$ |
| MIP-3 $\beta$ | $21.8 \% \pm 8.5$ | $-5.6 \% \pm 11.2$ | $-7.4 \% \pm 5.7$ |
| MIP-2 | $-37.0 \% \pm 6.1$ | $-35.4 \% \pm 2.1$ | $-44.7 \% \pm 3.2$ |
| IP-10 | $-58.8 \% \pm 6.3$ | $-77.3 \% \pm 3.2$ | $-62.7 \% \pm 4.9$ |
| RANTES | $-73.4 \% \pm 5.3$ | $-71.5 \% \pm 3.4$ | $-73.9 \% \pm 1.7$ |
| MDC | $45.2 \pm 39.4$ | $-23.8 \pm 7.6$ | $-45.5 \pm 7.5$ |
| MCP-5 | $-71.2 \% \pm 2.6$ | $-79.9 \% \pm 1.5$ | $-83.1 \% \pm 1.5$ |
| MIP-1 $Y$ | $-78.3 \% \pm 2.9$ | $-84.5 \% \pm 2.9$ | $-83.0 \% \pm 0.2^{* * *}$ |
| GCP-2 | - | $-94.8 \% \pm 1.0$ | $-95.5 \% \pm 16.7^{* * *}$ |
| MIP-1 $\beta$ | $-45.9 \% \pm 7.5$ | $-66.4 \% \pm 3.6$ | $-80.7 \% \pm 1.5$ |
| Anti-inflammatory | 6 h Untreated | 24h Untreated | 72 h Untreated |
| $\operatorname{lgG~A}$ | $68.6 \% \pm 50.8$ | 16.6\% $\pm 6.8$ | $49.3 \% \pm 16.0$ |
| IL-4 | - | - | - |
| IL-10 | - | - | - |
| IL-2 | - | - | - |
| Pleiotropic /others | 6 h Untreated | 24h Untreated | 72h Untreated |
| LIF | -30.8\% $\pm 4.7$ | $-19.5 \% \pm 11.7$ | -19.1\% ${ }^{\text {a }}$.9 |
| TIMP1 | $10.1 \% \pm 15.0$ | $-62.5 \% \pm 4.0$ | $-61.8 \% \pm 1.7^{*}$ |
| IL-11 | $-48.7 \% \pm 3.8$ | $-71.5 \% \pm 0.1$ | $-55.5 \% \pm 1.6$ |
| IL-7 | - | $-23.9 \% \pm 3.1$ | $-34.4 \% \pm 2.7$ |
| VCAM1 | $-54.4 \% \pm 5.8$ | $-47.3 \% \pm 6.2$ | $-46.0 \% \pm 3.6$ |
| GST- $\alpha$ | - | - | - |
| CD40 | - | - | - |
| MMP 9 | - | - | - |
| Myoglobin | - | - | - |
| Apolipoprotein A-I | - | - | - |
| SGOT | - | - | - |

Supplementary table 2

| Mitogens | 6h LPS/IFNY | 24h LPS/IFNY | 72h LPS/IFNY |
| :---: | :---: | :---: | :---: |
| CRP mouse | $62.8 \% \pm 44.5$ | $82.3 \% \pm 47.9$ * | $11.0 \% \pm 15.6$ |
| M-CSF | $60.9 \% \pm 3.2$ | $-14.3 \% \pm 37.7$ | $-21.1 \% \pm 4.0^{*}$ |
| EGF | $35.2 \% \pm 2.8$ | 29.1\% $\pm 33.8$ | $-31.6 \% \pm 6.8{ }^{* * *}$ |
| IL-3 | $29.2 \% \pm 10.8$ | $-22.6 \% \pm 37.8$ | $-49.8 \% \pm 3.1^{* * *}$ |
| FGF basic | $5.6 \% \pm 13.0$ | $-30.5 \% \pm 17.6$ | $-57.8 \% \pm 2.1{ }^{* * *}$ |
| SCF | $-3.4 \% \pm 1.5$ | $32.0 \% \pm 49.0$ | $-4.7 \% \pm 3.5$ |
| GM-CSF | $-3.4 \% \pm 35.6$ | $-20.3 \% \pm 39.0$ | $-88.1 \% \pm 1.2^{* * *}$ |
| FGF-9 | $-8 \% \pm 11.8$ | $-29.1 \% \pm 30.6$ | $-57.3 \% \pm 1.1^{* * *}$ |
| TPO | - | -61.4\%11.8** | $-72.0 \% \pm 4.7$ *** |
| IL-5 | - | - | - |
| Pro-inflammatory | 6h LPS/IFNY | 24h LPS/IFNY | 72h LPS/IFNY |
| IFN Y | $101.8 \% \pm 67$ | $34.2 \% \pm 62.9$ | -92.4\% ${ }^{\text {0 }}$.1 *** |
| IL-17a | $18.8 \% \pm 8.6$ | $-59.5 \% \pm 17.6^{* *}$ | $-80.3 \% \pm 0.5^{\text {*** }}$ |
| Oncostatin M | $16.2 \% \pm 3.1$ | $47.5 \% \pm 53.6$ | $4.0 \% \pm 3.0$ |
| IL-6 | $-6.4 \% \pm 12.4$ | $-77.8 \% \pm 10.9^{* * *}$ | $-93.9 \% \pm 0.5^{* * *}$ |
| IL-12p70 | $-9.7 \% \pm 4.0$ | $-44.3 \% \pm 25.8$ | $-72.3 \% \pm 1.9^{* * *}$ |
| $\mathrm{IL}-1 \alpha$ | $-14.9 \% \pm 3.2$ | $-6.0 \% \pm 40.4$ | $-70.0 \% \pm 2.2$ *** |
| IL-18 | $-40.6 \% \pm 18.6$ | $15.6 \% \pm 74.5$ | $-90.2 \% \pm 4.9^{* *}$ |
| TNF $\alpha$ | $-43.8 \% \pm 1.9$ | $-53.3 \% \pm 18.9$ ** | $-71.4 \% \pm 1.8^{* * *}$ |
| CD40 ligand | - | $28.8 \% \pm 76.4$ | 21.0\% $\pm 50.0$ |
| IL-1 $\beta$ | - | $-66.3 \% \pm 18.3$ | $-53.8 \% \pm 3.5^{* *}$ |
| Vascular/haematological | 6h LPS/IFNY | 24h LPS/IFNY | 72h LPS/IFNY |
| Tissue Factor | $215.4 \% \pm 79$ | $-69.1 \% \pm 12.2^{* *}$ | $-72.6 \% \pm 6.2$ *** |
| Haptoglobin | $53.2 \% \pm 23.1$ | $143.0 \% \pm 19.4$ | $74.3 \% \pm 26.7$ |
| VEGF | $30 \% \pm 6.4$ | $-44.8 \% \pm 25.1$ | $-76.0 \% \pm 1.9^{* * *}$ |
| Endothelin | $23 \% \pm 19.1$ | $-43.3 \% \pm 28.4$ | $-68.2 \% \pm 4.4^{* * *}$ |
| Factor VII | $8.5 \% \pm 6.8$ | $1.8 \% \pm 28.7$ | $-42.4 \% \pm 3.5^{* * *}$ |
| Fibrinogen | $5.0 \% \pm 0.6$ | $80.1 \% \pm 31.7^{* * *}$ | $5.6 \% \pm 5.0$ |
| MPO | - | - | - |
| SAP | - | - | - |
| vWF | - | - | - |
| Chemokines | 6h LPS/IFNY | 24h LPS/IFNY | 72h LPS/IFNY |
| Eotaxin | 73.5\% $\pm 48.0$ | $-71.03 \% \pm 12.3$ *** | $-71.7 \% \pm 2.8^{* * *}$ |
| MIP-1 $\alpha$ | $61.0 \% \pm 3.2$ | $-81.5 \% \pm 8.0^{* *}$ | $-70.5 \% \pm 1.1^{* * *}$ |
| MCP-3 | $46.7 \% \pm 54.5$ | $-26.7 \% \pm 35.1$ | $-63.9 \% \pm 2.3^{* * *}$ |
| MCP-1 | $46.7 \% \pm 4.8$ | $-40.9 \% \pm 28.5$ | $-73.5 \% \pm 1.4^{* * *}$ |
| KC/GRO $\alpha$ | $29.7 \% \pm 32.8$ | $-27.5 \% \pm 35.6$ | $-74.4 \% \pm 3.7^{\text {*** }}$ |
| Lymphotactin | 28.6\% $\pm 6.0$ | $40.4 \% \pm 46.7$ | $-3.6 \% \pm 4.0$ |
| MIP-3 $\beta$ | $19.4 \% \pm 5.7$ | $-67.2 \% \pm 10.5^{* * *}$ | $-73.2 \% \pm 0.9^{* * *}$ |
| MIP-2 | $19.3 \% \pm 41.3$ | $-51.2 \% \pm 23.7^{*}$ | $-86.4 \% \pm 2.1^{* * *}$ |
| IP-10 | 15.4\% $\pm 8.4$ | $-22.8 \% \pm 29.4$ | $-48.7 \% \pm 5.6^{* * *}$ |
| RANTES | $-9.9 \% \pm 22.6$ | $-29.8 \% \pm 33.7$ | $-66.5 \% \pm 3.4^{* * *}$ |
| MDC | $-22.5 \pm 12.6$ | $-90.4 \pm 4.2^{* * *}$ | $-86.4 \pm 3.2^{* * *}$ |
| MCP-5 | $-27.8 \% \pm 12.6$ | $-62.5 \% \pm 17.8$ | $-67.7 \% \pm 0.9^{* * *}$ |
| MIP-1 $Y$ | $-52.4 \% \pm 6.5$ | $-75.2 \% \pm 11.6^{* * *}$ | $-55.0 \% \pm 5.7^{* * *}$ |
| GCP-2 | $-57.8 \% \pm 16.7$ | $-87.9 \% \pm 5.8^{* * *}$ | $-84.4 \% \pm 0.8^{* * *}$ |
| MIP-1 $\beta$ | -70.1\% $\pm 2.4$ | $-88.9 \% \pm 4.8^{* * *}$ | $-81.7 \% \pm 1.4^{* * *}$ |
| Anti-inflammatory | 6h LPS/IFNY | 24h LPS/IFNY | 72h LPS/IFNY |
| $\operatorname{lgG}$ A | $123.8 \% \pm 46.4$ | $130.2 \% \pm 70.5^{* *}$ | $49.7 \% \pm 11.8$ |
| IL-4 | $57.9 \% \pm 32.2$ | $1.3 \% \pm 31.1$ | $-45.0 \% \pm 3.5^{* * *}$ |
| IL-10 | $36.1 \% \pm 14.9$ | $-48.3 \% \pm 23.6^{*}$ | $-75.4 \% \pm 0.9^{* * *}$ |
| IL-2 | $5.2 \% \pm 6.6$ | $-49.4 \% \pm 23.8^{* *}$ | $-77.3 \% \pm 0.7^{* * *}$ |
| Pleiotropic /others | 6 h LPS/IFNY | 24h LPS/IFNY | 72h LPS/IFNY |
| LIF | $40.1 \% \pm 15.0$ | $-31.8 \% \pm 30.3$ | $-72.3 \% \pm 1.5{ }^{* * *}$ |
| TIMP1 | $32.1 \% \pm 32.8$ | $-57.9 \% \pm 20.8$ * | $-62.5 \% \pm 2.0^{* * *}$ |
| IL-11 | 27.0\% $\pm 6.9$ | $-37.0 \% \pm 26.7$ | $-72.4 \% \pm 4.8^{* * *}$ |
| IL-7 | $6.5 \% \pm 2.7$ | 20.6\% $\pm 41.9$ | $-13.9 \% \pm 1.4$ |
| VCAM1 | $-2.0 \% \pm 9.1$ | $-48.3 \% \pm 22.3^{* *}$ | $-51.5 \% \pm 2.8^{* * *}$ |
| GST- $\alpha$ | - | $-27.0 \% \pm 30.1$ | $-47.2 \% \pm 15.7$ |
| CD40 | - | $-52.0 \% \pm 21.4$ | $-84.8 \% \pm 2.9^{* * *}$ |
| MMP 9 | - | $-85.1 \% \pm 8.6^{* * *}$ | $-82.2 \% \pm 0.3^{* * *}$ |
| Myoglobin | - | - | - |
| Apolipoprotein A-I | - | - | - |
| SGOT | - |  | - |

